Phase II trial of GTX chemotherapy in metastatic pancreatic cancer

被引：0
|
作者：
Fine, R.
Moorer, G.
Sherman, W.
Chu, K.
Maurer, M.
Chabot, J.
Postolov, I.
Prowda, J.
Schreibman, S.
Levitz, J.
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Morristown Mem Hosp, Morristown, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4623
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
    Nakamura, K.
    Yamaguchi, T.
    Ishihara, T.
    Sudo, K.
    Kato, H.
    Saisho, H.
    BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1575 - 1579
  • [32] Phase II trial of gemcitabine, epirubicin, and G-CSF in patients with metastatic pancreatic cancer
    Raderer, M
    Kornek, GV
    Valencak, J
    Lenauer, A
    Flebiger, W
    Greul, R
    Lang, F
    Schneeweiss, B
    Depisch, D
    Scheithauer, W
    ANNALS OF ONCOLOGY, 1998, 9 : 169 - 169
  • [33] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
    Bécouarn, Y
    Ychou, M
    Ducreux, M
    Borel, C
    Bertheault-Cvitkovic, F
    Seitz, JF
    Nasca, S
    Nguyen, TD
    Paillot, B
    Raoul, JL
    Duffour, J
    Fandi, A
    Dupont-André, G
    Rougier, P
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
  • [34] Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy
    Michael, M
    Bishop, JF
    Levi, JA
    Bell, DR
    Zalcberg, JR
    Friedlander, ML
    Olver, IN
    Smith, JG
    Toner, GC
    MEDICAL JOURNAL OF AUSTRALIA, 1997, 166 (10) : 520 - 523
  • [35] Randomized phase II trial of an oral factor Xa inhibitor in patients with metastatic cancer on chemotherapy
    Levine, M. N.
    Liebman, H. A.
    Esclanate, C. P.
    Julian, J. A.
    Deitchman, D.
    O'Brien, M. C.
    Ramirez, L. M.
    THROMBOSIS RESEARCH, 2010, 125 : S161 - S162
  • [36] A phase II trial of oral combination chemotherapy with capecitabine and cyclophosphamide (XC) in metastatic breast cancer
    Hirata, M.
    Takao, S.
    Okamoto, Y.
    Yamashita, S.
    Kawaguchi, Y.
    Takami, M.
    Furusawa, H.
    Abe, C.
    Sakamoto, J.
    Yoshimoto, M.
    EJC SUPPLEMENTS, 2010, 8 (03): : 197 - 197
  • [37] Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: A phase I and II trial
    Reni, M
    Panucci, MG
    Passoni, P
    Bonetto, E
    Nicoletti, R
    Ronzoni, M
    Zerbi, A
    Staudacher, C
    Di Carlo, V
    Villa, E
    CANCER INVESTIGATION, 2004, 22 (05) : 688 - 696
  • [38] A phase II study of modified FOLFIRINOX for chemotherapy-na⟨ve patients with metastatic pancreatic cancer
    Ozaka, Masato
    Ishii, Hiroshi
    Sato, Tosiya
    Ueno, Makoto
    Ikeda, Masafumi
    Uesugi, Kazuhiro
    Sata, Naohiro
    Miyashita, Kouichirou
    Mizuno, Nobumasa
    Tsuji, Kunihiro
    Okusaka, Takuji
    Furuse, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1017 - 1023
  • [39] A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
    Masato Ozaka
    Hiroshi Ishii
    Tosiya Sato
    Makoto Ueno
    Masafumi Ikeda
    Kazuhiro Uesugi
    Naohiro Sata
    Kouichirou Miyashita
    Nobumasa Mizuno
    Kunihiro Tsuji
    Takuji Okusaka
    Junji Furuse
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 1017 - 1023
  • [40] Final results of a phase II trial of raltitrexedeloxatin (TOM-OX) salvage chemotherapy in gemcitabine-refractory metastatic pancreatic cancer (PC)
    Reni, Michele
    Bonetto, Elisa
    Pasetto, Lara
    Aprile, Giuseppe
    Cordio, Stefano
    Passoni, Paolo
    Dell'Oro, Stefania
    Luppi, Gabriele
    Milandri, Carlo
    Fugazza, Clara
    ANNALS OF ONCOLOGY, 2005, 16 : 55 - 55
12345